J. Safra Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-310,817
Closed -$25.2M 402
2025
Q1
$25.2M Buy
310,817
+18,315
+6% +$1.64M 2.05% 15
2024
Q4
$26.3M Buy
292,502
+240,415
+462% +$23.3M 2.14% 14
2024
Q3
$5.13M Buy
52,087
+48,513
+1,357% +$4.77M 0.49% 22
2024
Q2
$331K Hold
3,574
0.03% 46
2024
Q1
$339K Hold
3,574
0.04% 32
2023
Q4
$319K Hold
3,574
0.04% 28
2023
Q3
$261K Hold
3,574
0.04% 31
2023
Q2
$297K Hold
3,574
0.04% 32
2023
Q1
$272K Sell
3,574
-373,854
-99% -$31M 0.04% 28
2022
Q4
$31.3M Sell
377,428
-70,572
-16% -$5.71M 5.51% 8
2022
Q3
$35.5M Buy
448,000
+3,000
+0.7% +$253K 5.62% 8
2022
Q2
$33.1M Buy
+445,000
New +$33.4M 5.13% 8

Other funds holding XBI

J. Safra Asset Management's XBI Position: Q2 2025 in Review

J. Safra Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2025, closing a stake of 310,817 shares — an estimated $25.2M sold.

J. Safra Asset Management first reported a position in XBI in Q2 2022 and held it in 12 quarters. The position peaked at $35.5M in Q3 2022. 625 funds tracked by Wall St. Rank hold XBI as of Q2 2025.

  • J. Safra Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2025 after selling out during the quarter.
  • J. Safra Asset Management sold 310,817 State Street SPDR S&P Biotech ETF shares in Q2 2025, an estimated $25.2M.
  • J. Safra Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 12 quarters.
  • J. Safra Asset Management's State Street SPDR S&P Biotech ETF position peaked at $35.5M in Q3 2022.
  • 625 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2025.

Based on J. Safra Asset Management's 13F filing for Q2 2025, filed 28 Jul 2025.